Accelerating drug discovery innovation via advanced data science solutions – a case study of Almirall (global pharma company) and Biorelate (data science solutions provider)

Almirall, a global pharmaceutical company dedicated to medical dermatology, works with Biorelate, the leading provider of knowledge-based drug discovery solutions, to help expand their data science strategy and underpin an innovative pipeline of new novel targets as well as new novel applications for existing medicines.

Leveraging the most reliable sources of prior knowledge is a critical element of Almirall’s data science strategy and they have enlisted Biorelate, with its cutting-edge AI platform, Galactic AI™, to help accelerate their R&D innovation and productivity.

Francesc Fernandez Albert, Senior Director R&D Data Science at Almirall: “At Almirall we appreciate that the future of successful drug discovery hinges on using the best data science methodologies and available data evidence to inform target identification and other R&D activities. The Galactic AI™ knowledge graph is a critical source of evidence for our therapeutic hypotheses. It is an important element in our AI and data science strategy to ensure the information that we use is the highest quality available and provides good explainability.”

Ben Sidders, Chief Scientific Officer at Biorelate: “The future success of R&D depends on accessing the best quality insights to inform drug development decisions, making smarter data science & AI strategies critical for pipeline success. We are delighted to work with Almirall, a leader in dermatological medicine, to enable more efficient, reliable and translatable in-depth biological research and analysis.”

Almirall chose to partner with Biorelate due to Galactic AI™’s capability to reveal intricate cause-and-effect relationships between biological entities and concepts, such as genes, diseases, and drugs. This in-depth data is provided directly to users, rather than being hidden behind a dashboard, enabling the pharmaceutical company to rank and prioritize targets with stronger and more reliable evidence.
‍
Sergi Picart Armada, Senior Artificial Intelligence Scientist at Almirall: “Biorelate and Galactic AI™ stand out because of their ability to identify cause-and-effect pathways, allowing us to connect biological concepts and entities with detailed evidence and traceability. Additionally, access to complete raw data sets this solution apart from other existing tools".

Bruna Oriol Tordera, Senior Data Scientist at Almirall: “Biorelate has a world-class Professional Services team, who go above and beyond in their customer service to help us fully leverage the uniquely rich data from Galactic AI™.”

To learn more about Biorelate and Galactic AI™, visit www.biorelate.com
For more information about Almirall, please visit https://www.almirall.com/‍

About Almirall
Almirall is a global pharmaceutical company dedicated to medical dermatology. We closely collaborate with leading scientists, healthcare professionals, and patients to deliver our purpose: to transform the patients' world by helping them realize their hopes and dreams for a healthy life. We are at the forefront of science to deliver ground-breaking, differentiated medical dermatology innovations that address patients´ needs.
‍
Almirall, founded in 1944 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange (ticker: ALM, total revenue in 2024: €990 MM, over 2000 employees globally). Almirall products help to improve the lives of patients every day and are available in over 100 countries.

About Biorelate
Biorelate is a world leader in leveraging advanced data science methods to extract critical knowledge from vast amounts of pharmaceutical data and literature, significantly enhancing the discovery of novel biopharmaceuticals.

Biorelate offers multiple product lines powered by its proprietary platform, Galactic AI™. Galactic AI™ employs sophisticated natural language processing (NLP) and artificial intelligence (AI) to uncover hidden cause- and-effect relationships across over 40 million published biomedical sources. This innovative platform provides unprecedented insights into disease pathways, enabling more precise and effective drug discovery. 

‍